CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
Prnewswire·2026-03-26 13:32
Breakthroughs in Local Manufacturing and Reimbursement Access Emerging Preclinical Innovation Pipeline Three internally developed next-generation ADC candidates—CS5007 (EGFR/HER3 ADC), CS5008 (SSTR2/DLL3 ADC), and CS5006 (ITGB4 ADC)—will present preclinical research findings at AACR 2026, with IND submissions planned for 2026. Solid Financial Position SUZHOU, China, March 26, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the res ...